128 related articles for article (PubMed ID: 35426868)
21. Bevacizumab is active as a single agent against recurrent malignant gliomas.
Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
[TBL] [Abstract][Full Text] [Related]
22. Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.
Motoo N; Hayashi Y; Shimizu A; Ura M; Nishikawa R
Jpn J Clin Oncol; 2019 Dec; 49(11):1016-1023. PubMed ID: 31665343
[TBL] [Abstract][Full Text] [Related]
23. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
24. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Bokstein F; Shpigel S; Blumenthal DT
Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820
[TBL] [Abstract][Full Text] [Related]
25. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
Reardon DA; Herndon JE; Peters K; Desjardins A; Coan A; Lou E; Sumrall A; Turner S; Sathornsumetee S; Rich JN; Boulton S; Lipp ES; Friedman HS; Vredenburgh JJ
J Neurooncol; 2012 Mar; 107(1):213-21. PubMed ID: 21997879
[TBL] [Abstract][Full Text] [Related]
26. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
[TBL] [Abstract][Full Text] [Related]
28. Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Nagane M; Kobayashi K; Tanaka M; Tsuchiya K; Shishido-Hara Y; Shimizu S; Shiokawa Y
Int J Clin Oncol; 2014 Feb; 19(1):16-23. PubMed ID: 23354833
[TBL] [Abstract][Full Text] [Related]
29. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
Chamberlain MC; Johnston S
J Neurooncol; 2009 Feb; 91(3):359-67. PubMed ID: 18953491
[TBL] [Abstract][Full Text] [Related]
30. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
Chen C; Huang R; MacLean A; Muzikansky A; Mukundan S; Wen PY; Norden AD
J Neurooncol; 2013 Nov; 115(2):267-76. PubMed ID: 23974656
[TBL] [Abstract][Full Text] [Related]
31. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location.
Matsuda M; Ishikawa E; Yamamoto T; Akutsu H; Takano S; Matsumura A
J Clin Neurosci; 2017 Jun; 40():115-119. PubMed ID: 28246006
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
34. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
[TBL] [Abstract][Full Text] [Related]
36. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
de Marcellus C; Tauziède-Espariat A; Cuinet A; Pasqualini C; Robert MP; Beccaria K; Puget S; Boddaert N; Figarella-Branger D; De Carli E; Bourdeaut F; Leblond P; Fouyssac F; Andre N; Bertozzi AI; Butel T; Dufour C; Valteau-Couanet D; Varlet P; Grill J
J Neurooncol; 2022 Apr; 157(2):355-364. PubMed ID: 35239111
[TBL] [Abstract][Full Text] [Related]
37. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.
Burger MC; Mildenberger IC; Wagner M; Mittelbronn M; Steinbach JP; Bähr O
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353668
[TBL] [Abstract][Full Text] [Related]
40. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
Mantica M; Pritchard A; Lieberman F; Drappatz J
J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
